Juvenal Tobin W, Chief Commercial Officer of Castle Biosciences Inc., sold 1,730 common shares on August 17 under a Rule 10b5-1 trading plan adopted on December 10, 2025. The disposal occurred at prices ranging from $29.21 to $30.01 per share, with a weighted average sale price of $29.59, totaling $51,190.
Following the transaction, Tobin W retains direct ownership of 75,964 Castle Biosciences shares. The company’s stock was trading near $35 at the time of the sale, reflecting a 64% increase over the prior 12 months.
Castle Biosciences reported adjusted losses of $0.07 per share in the second quarter, outperforming market expectations of a $0.40 loss. Revenue reached $103.5 million, exceeding the projected $86.4 million. The company also raised its full-year sales guidance and noted a 63% year-over-year increase in TissueCypher franchise volumes, along with a 28% sequential rise.
Analysts at BTIG raised the price target on Castle Biosciences to $44 from $40, maintaining a buy rating. The upgrade cited revenue performance 20% above expectations and sustained company growth.
